Study of the Metabolism of Danicopan in Healthy Adults

A 2-Part, Open-Label, Randomized, Single-Dose, 3-Period Crossover, Phase 1, Relative Bioavailability, and Food Effect Study, Comparing Different Formulations of Danicopan in Healthy Adult Subjects

This is a 2-part open-label, randomized, single-dose, 3-sequence, 3-period crossover, relative bioavailability, and food-effect study comparing different formulations of danicopan in healthy adult participants.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Danicopan: Powder-In-Capsule 1; Drug: Danicopan: Tablet; Drug: Danicopan: Powder-In-Capsule 2

Detailed Description

For both parts of this study, on Day 1 of each period, participants will receive a single oral dose of danicopan as either the prototype powder-in-capsule (PIC) formulation (1 or 2) under fed conditions, the prototype PIC formulation (1 or 2) under fasting conditions, or the tablet formulation under fed conditions.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tempe, Arizona, United States, 85283
      • Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. No clinically significant findings at screening (medical history, clinical laboratory profiles, and electrocardiograms).
2. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive, with a minimum body weight of 50.0 kg at screening.
3. Female participants of childbearing potential must either agree to abstinence or to use, with their male partner, a highly effective method of contraception .
4. Non-sterile male participants must agree to abstinence or use a highly effective method of contraception.

Exclusion Criteria:

1. History of any medical or psychiatric condition or disease that might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study.
2. History or presence of drug or alcohol abuse within previous 2 years, current tobacco user, or positive drugs-of-abuse screen or alcohol screen at screening or Day -1 of Period 1.
3. History of meningococcal infection, or a first-degree relative with a history of meningococcal infection.
4. History of procedures that could alter absorption or excretion of orally administered drugs.
5. History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs.
6. Body temperature ≥ 38.0°Celcius at screening or prior to first dosing or history of febrile illness, or other evidence of infection, within 14 days prior to (first) dosing.
7. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days before first dosing, whichever is longer.
8. Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days before first dosing, receipt of blood products within 6 months prior to first dosing, or receipt of a vaccine within 30 days prior to first dosing.
9. Is a female with a positive pregnancy test or who is lactating.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Sequence 1; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Powder-In-Capsule 1; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)
Experimental: Part 1: Sequence 2; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Powder-In-Capsule 1; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)
Experimental: Part 1: Sequence 3; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Powder-In-Capsule 1; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)
Experimental: Part 2: Sequence 1; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Powder-In-Capsule 2; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)
Experimental: Part 2: Sequence 2; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Powder-In-Capsule 2; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)
Experimental: Part 2: Sequence 3; Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows: Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions. There will be a washout period of at least 5 days between each danicopan dosing.	Drug: Danicopan: Tablet; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly); Drug: Danicopan: Powder-In-Capsule 2; Danicopan (200 milligrams) will be administered orally on Day 1.; Other Names: ALXN2040; ACH-0144471 (formerly)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relative Bioavailability Of Danicopan Prototype PIC 1 Formulation And Tablet Formulation	The relative bioavailability of the PIC 1 formulation versus the tablet formulation will be measured by the ratio of select pharmacokinetic (PK) parameters: maximum observed plasma concentration (Cmax), area under the concentration-time curve from time of administration to the last measurable concentration (AUC0-t), and area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf).	Up to 72 hours postdose
AUC0-inf Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
AUC0-t Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
Cmax Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
Time to maximum observed plasma concentration (Tmax) Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
Relative Bioavailability Of Danicopan Prototype PIC 2 Formulation And Tablet Formulation	The relative bioavailability of the PIC 2 formulation versus the tablet formulation will be measured by the ratio of select PK parameters: Cmax, AUC0-t, and AUC0-inf.	Up to 72 hours postdose
AUC0-inf Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
AUC0-t Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
Cmax Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose
Tmax Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions		Up to 72 hours postdose

Secondary Outcome Measures

Outcome Measure	Time Frame
Number Of Participants Receiving Prototype PIC 1 And Tablet With Treatment-emergent Adverse Events Under Fed Conditions	Day 1 (postdose) through follow-up (10 [+/- 2] days dosing on Day 1)
Number Of Participants Receiving Prototype PIC 1 With Treatment-emergent Adverse Events Under Fasted Conditions	Day 1 (postdose) through follow-up (10 [+/- 2] days dosing on Day 1)
Number Of Participants Receiving Prototype PIC 2 And Tablet With Treatment-emergent Adverse Events Under Fed Conditions	Day 1 (postdose) through follow-up (10 [+/- 2] days dosing on Day 1)
Number Of Participants Receiving Prototype PIC 2 With Treatment-emergent Adverse Events Under Fasted Conditions	Day 1 (postdose) through follow-up (10 [+/- 2] days dosing on Day 1)

Collaborators and Investigators

• Sponsor: Alexion Pharmaceuticals
• Collaborators: Celerion

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2020
• Primary Completion (Actual): December 7, 2020
• Study Completion (Actual): December 7, 2020

Study Registration Dates

• First Submitted: October 26, 2020
• First Submitted That Met QC Criteria: October 26, 2020
• First Posted (Actual): October 30, 2020

Study Record Updates

• Last Update Posted (Actual): April 15, 2022
• Last Update Submitted That Met QC Criteria: April 8, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Bioavailability; Capsule; Danicopan; Factor D Inhibitor; Food Effect; Tablet
• Other Study ID Numbers: ALXN2040-HV-119

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No